TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8160603

Group type: EXPERIMENTAL
Intervention: Simultaneous monophasic shocks
Number of subjects: 5

Group type: COMPARATOR
Intervention: Sequential monophasic shocks
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Monophasic shocks with bidirectional lead configuration
Number of subjects: 5

Group type: COMPARATOR
Intervention: Biphasic shocks with bidirectional lead configuration
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Monophasic shocks with unidirectional lead configuration
Number of subjects: 5

Group type: COMPARATOR
Intervention: Biphasic shocks with unidirectional lead configuration
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Unipolar transvenous defibrillation lead system ('active can')
Number of subjects: 5

Group type: COMPARATOR
Intervention: Standardized unidirectional lead configuration
Number of subjects: 5
Study: 3046587

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Multiple insulin injections (MI)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional insulin treatment (CIT)
Number of subjects: 45
Study: 29016150

Group type: EXPERIMENTAL
Intervention: Counterstereotypic imagined intergroup contact
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stereotypic imagined intergroup contact
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 26823484

Group type: EXPERIMENTAL
Intervention: New-generation drug-eluting stents
Number of subjects: 6081

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 6081

Group type: COMPARATOR
Intervention: Nondiabetic patients
Number of subjects: 6081
Study: 26182820

Group type: EXPERIMENTAL
Intervention: Indian turmeric powder with honey
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study: 22592178

Group type: EXPERIMENTAL
Intervention: Bikram yoga training (24 sessions in 8 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 21
Study: 21739240

Group type: EXPERIMENTAL
Intervention: Modified-policosanol (MP) 20 mg daily with background statin therapy
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Modified-policosanol (MP) 20 mg daily as monotherapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo with background statin therapy
Number of subjects: 54
Study: 19564517

Group type: EXPERIMENTAL
Intervention: Patients who have been tested for HIV
Number of subjects: 2107

Group type: EXPERIMENTAL
Intervention: Demographic characteristics affecting HIV testing history
Number of subjects: 2107

Group type: EXPERIMENTAL
Intervention: Age relationship to HIV testing history
Number of subjects: 2107

Group type: EXPERIMENTAL
Intervention: Education years relation to HIV testing history
Number of subjects: 2107
Study: 17024505

Group type: EXPERIMENTAL
Intervention: Ertapenem (1 g daily)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Cefepime (2 g every 12 h with optional metronidazole 500 mg every 12 h)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 303

Group type: COMPARATOR
Intervention: Cefepime
Number of subjects: 303
Study: 15219514

Group type: EXPERIMENTAL
Intervention: Intracoronary injection of autologous bone marrow mesenchymal stem cell
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard saline
Number of subjects: 69
Study: 11174623

Group type: EXPERIMENTAL
Intervention: First-phase insulin release during IV-GTT
Number of subjects: 59600

Group type: EXPERIMENTAL
Intervention: Children <8 years
Number of subjects: 59600

Group type: EXPERIMENTAL
Intervention: Subjects 8 to 20 years
Number of subjects: 59600
Study: 9287229

Group type: EXPERIMENTAL
Intervention: Stent placement
Number of subjects: 220

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 220
Study: 8501503

Group type: EXPERIMENTAL
Intervention: VCMP/VBAP combination chemotherapy
Number of subjects: 487

Group type: COMPARATOR
Intervention: MP (melphalan-prednisone)
Number of subjects: 487
Study: 3226837

Group type: EXPERIMENTAL
Intervention: Proximity to sugar
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control conditions (additional controls added)
Number of subjects: 90
Study: 30005643

Group type: EXPERIMENTAL
Intervention: Peer support intervention with monthly group education on diabetic retinopathy (DR) and individual reminders for eye examination
Number of subjects: 700

Group type: COMPARATOR
Intervention: Usual care practices alone
Number of subjects: 700
Study: 28511614

Group type: EXPERIMENTAL
Intervention: NTP-CE (new topical panthenol-containing emollient)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Reference emollient
Number of subjects: 108
Study: 25626962

Group type: EXPERIMENTAL
Intervention: Fixation of both the clavicle and the scapular neck (group A)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Fixation of the clavicle alone (group B)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conservative treatment (group C)
Number of subjects: 39
Study: 23107362

Group type: EXPERIMENTAL
Intervention: Counseling in Dialogue (CD)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Care as Usual (CU)
Number of subjects: 94
Study: 17148515

Group type: EXPERIMENTAL
Intervention: Rehabilitation in the home setting (9 hours/week for three weeks)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Day clinic rehabilitation
Number of subjects: 58
Study: 12535822

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/daily
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/daily
Number of subjects: 110

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 110
Study: 10825055

Group type: EXPERIMENTAL
Intervention: Thalidomide (400 mg/d for 1 week, then 200 mg/d for 7 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 16
Study: 7595132

Group type: EXPERIMENTAL
Intervention: Kaliuretic peptide (100 ng/kg body weight/min for 60 min)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Long acting natriuretic peptide (100 ng/kg body weight/min for 60 min)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) (100 ng/kg body weight/min for 60 min)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vessel dilator (100 ng/kg body weight/min for 60 min)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Kaliuretic peptide, ANF, and long acting natriuretic peptide (100 ng/kg body weight/min for 60 min)
Number of subjects: 30
Study: 2125605

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg once daily for 1 week
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg once daily for 1 week
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pravastatin and Lovastatin
Number of subjects: 20
Study: 7382968

Group type: EXPERIMENTAL
Intervention: i.m. ribostamycin
Number of subjects: 30

Group type: COMPARATOR
Intervention: i.m. gentamycin
Number of subjects: 30
Study: 29460236

Group type: EXPERIMENTAL
Intervention: XEN-D0103 50 mg bd
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 27124878

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% QD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle BID
Number of subjects: 0
Study: 25591488

Group type: EXPERIMENTAL
Intervention: Electrofusion
Number of subjects: 221

Group type: COMPARATOR
Intervention: Conventional technique (diathermy or cold scalpel)
Number of subjects: 221
Study: 22968837

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 39

Group type: COMPARATOR
Intervention: Relaxation therapy
Number of subjects: 39
Study: 20583937

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine 0.125% with fentanyl 100 microg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Epidural ropivacaine 0.2% with fentanyl 100 microg
Number of subjects: 80
Study: 17976714

Group type: EXPERIMENTAL
Intervention: Dominant-related targets in the absence of a biasing context
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both dominant- and subordinate-related targets in the absence of a biasing context
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dominant-related targets in the presence of a biasing context
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both dominant- and subordinate-related targets in the presence of a biasing context
Number of subjects: 0
Study: 15990709

Group type: EXPERIMENTAL
Intervention: Silybin + vitamin E + phospholipids
Number of subjects: 85
Study: 12695268

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 21
Study: 10495843

Group type: EXPERIMENTAL
Intervention: VigiMouse visual performance test
Number of subjects: 6

Group type: COMPARATOR
Intervention: Visual analogue scale
Number of subjects: 6
Study: 7560236

Group type: EXPERIMENTAL
Intervention: 0.2% delmopinol hydrochloride
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine digluconate
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 1951080

Group type: EXPERIMENTAL
Intervention: OPC‐8212 (60 mg/day)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 6974386

Group type: EXPERIMENTAL
Intervention: 14-valent pneumococcal vaccine
Number of subjects: 827

Group type: COMPARATOR
Intervention: Control vaccine against Hemophilus influenzae type b
Number of subjects: 827
Study: 31498390

Group type: EXPERIMENTAL
Intervention: Project SEARCH + ASD Supports (PS + ASD) intervention
Number of subjects: 14

Group type: COMPARATOR
Intervention: Waitlist group (special education transition services)
Number of subjects: 14
Study: 29860928

Group type: EXPERIMENTAL
Intervention: Insight reappraisal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simple reappraisal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 27841849

Group type: EXPERIMENTAL
Intervention: Topical apraclonidine 0.5%
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 26072348

Group type: EXPERIMENTAL
Intervention: Goldmann isopters III4e, I4e, and I2e
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Octopus isopters III4e and I4e
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Humphrey mean deviation (MD)
Number of subjects: 154
Study: 23129812

Group type: EXPERIMENTAL
Intervention: Cervical spine manipulation
Number of subjects: 82

Group type: COMPARATOR
Intervention: Full manipulative group (mid-cervical, cervico-thoracic and thoracic joint manipulations)
Number of subjects: 82
Study: 20346703

Group type: EXPERIMENTAL
Intervention: PepCO(2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: PaCO(2)tc
Number of subjects: 60

Group type: COMPARATOR
Intervention: PaCO(2)tu
Number of subjects: 60
Study: 19809393

Group type: EXPERIMENTAL
Intervention: Friedreich Ataxia Rating Scale (FARS)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Gait parameters (velocity, cadence, stride length)
Number of subjects: 38
Study: 17760597

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNTA) injections at the vermilion border, 1 week before chemabrasion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control sides (no BoNTA injections)
Number of subjects: 12
Study: 15467100

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) rehydrated with Coca‐Cola
Number of subjects: 10

Group type: COMPARATOR
Intervention: Caffeine-free (CF) rehydrated with Caffeine‐Free Coca‐Cola
Number of subjects: 10
Study: 11169020

Group type: EXPERIMENTAL
Intervention: High-dose L-5-methyltetrahydrofolate (MTHF) at 17 mg/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Folic acid (FA) at 15 mg/day
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Folic acid (FA) at 2.4 mg/day (for RTRs)
Number of subjects: 50

Group type: COMPARATOR
Intervention: High-dose oral MTHF (17 mg/day) or FA (15 mg/day) (for HD patients)
Number of subjects: 50
Study: 9701162

Group type: EXPERIMENTAL
Intervention: 20 mg Zn with micronutrients (ZM)
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: 20 mg Zn alone (Z)
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Micronutrients alone (M)
Number of subjects: 740
Study: 7748921

Group type: EXPERIMENTAL
Intervention: Baseline examination including interviews, physical exams, and laboratory tests.
Number of subjects: 5632

Group type: EXPERIMENTAL
Intervention: Ongoing interim hospital discharge data survey and mortality survey.
Number of subjects: 5632
Study: 2812836

Group type: EXPERIMENTAL
Intervention: Lumbar epidural administration of fentanyl (1 microgram/kg body weight)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Intravenous administration of fentanyl (1 microgram/kg body weight)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 6
Study: 970905

Group type: EXPERIMENTAL
Intervention: Furosemide prophylaxis (20-60 mg) in the short-perfusion group (9 patients)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No furosemide prophylaxis in the short-perfusion group (15 patients)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Furosemide prophylaxis (20-60 mg) in the long-perfusion group (13 patients)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No furosemide prophylaxis in the long-perfusion group (11 patients)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Furosemide prophylaxis in the short-perfusion group
Number of subjects: 45

Group type: COMPARATOR
Intervention: No furosemide prophylaxis in the short-perfusion group
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Furosemide prophylaxis in the long-perfusion group
Number of subjects: 45

Group type: COMPARATOR
Intervention: No furosemide prophylaxis in the long-perfusion group
Number of subjects: 45
Study: 31841354

Group type: EXPERIMENTAL
Intervention: Capivasertib plus paclitaxel
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo plus paclitaxel
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Capivasertib plus paclitaxel in patients with PIK3CA/AKT1/PTEN-altered tumors
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo plus paclitaxel in patients with PIK3CA/AKT1/PTEN-altered tumors
Number of subjects: 140
Study: 30971437

Group type: EXPERIMENTAL
Intervention: Inulin-propionate ester (IPE)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inulin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cellulose
Number of subjects: 12
Study: 27981854

Group type: EXPERIMENTAL
Intervention: Disposable blades at 1500 rpm
Number of subjects: 48

Group type: COMPARATOR
Intervention: Reusable blades at 1500 rpm
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Total morcellation rate using disposable blades
Number of subjects: 48

Group type: COMPARATOR
Intervention: Single-use blades at 850 rpm
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Single-use blades at 1500 rpm
Number of subjects: 48
Study: 26409520

Group type: EXPERIMENTAL
Intervention: Transition-based context prompting
Number of subjects: 42

Group type: COMPARATOR
Intervention: Time-based prompting (every 5 minutes)
Number of subjects: 42
Study: 23985437

Group type: EXPERIMENTAL
Intervention: Dentifrice containing 1.5% arginine and 1450 ppm fluoride
Number of subjects: 284

Group type: COMPARATOR
Intervention: Positive control dentifrice containing 1450 ppm fluoride
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 284
Study: 22208783

Group type: EXPERIMENTAL
Intervention: Piroxicam 10 mg daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 18582572

Group type: EXPERIMENTAL
Intervention: Amoxicillin under fasting conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amoxicillin after intake at the beginning of breakfast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amoxicillin after breakfast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clavulanic acid under fasting conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clavulanic acid after intake at the beginning of breakfast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clavulanic acid after breakfast
Number of subjects: 0
Study: 16607936

Group type: EXPERIMENTAL
Intervention: Cerasorb (beta-tricalcium phosphate)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Autogenous bone graft
Number of subjects: 17
Study: 12828845

Group type: EXPERIMENTAL
Intervention: 0.5% PIR, b.i.d. for one week, then titrated to 1% PIR for one week, then 2% PIR for two weeks, and then for an additional 11 months
Number of subjects: 26

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: PIR (various concentrations)
Number of subjects: 26
Study: 10935581

Group type: EXPERIMENTAL
Intervention: DPNB ligated (group 1)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: DPNB preserved (group 2)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (group 3, unoperated)
Number of subjects: 28
Study: 8813918

Group type: EXPERIMENTAL
Intervention: 5% mannitol (group A)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 1.5% glycine (group B)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 2.7% sorbitol and 0.54% mannitol (group C)
Number of subjects: 59
Study: 1363664

Group type: EXPERIMENTAL
Intervention: Psychosomatic therapy (psychotherapy, relaxation, etc.) alone in group I (9 patients)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Psychosomatic therapy plus treatment with amineptine and clobazam in group II (9 patients)
Number of subjects: 18
Study: 3910303

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg + Acebutolol 100 mg
Number of subjects: 114

Group type: COMPARATOR
Intervention: Acebutolol 200 mg
Number of subjects: 114
Study: 29741576

Group type: EXPERIMENTAL
Intervention: Cluster-randomized trial methodology with a test-negative design (CR-TND)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional approaches to cluster-randomized trials
Number of subjects: 0
Study: 27485432

Group type: EXPERIMENTAL
Intervention: Conventional Treatment (CT) using bulk fill composite resin (Scotchbond™ Universal Adhesive system associated with Filtek Bulk Fill - 3 M/ESPE)
Number of subjects: 1214

Group type: COMPARATOR
Intervention: Atraumatic Restorative Treatment (ART) using high viscosity glass ionomer cement (Ketac Molar Easy Mix - 3 M/ESPE)
Number of subjects: 1214

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis between CT and ART
Number of subjects: 1214

Group type: EXPERIMENTAL
Intervention: Operator preferences regarding the techniques
Number of subjects: 1214
Study: 24262503

Group type: EXPERIMENTAL
Intervention: Group A (target cyclosporine level 600-700 ng/ml for first 6 months, 450-550 ng/ml for next 18 months)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Group B (target cyclosporine level 450-550 ng/ml for first 6 months, 300-400 ng/ml for next 18 months)
Number of subjects: 93
Study: 22993341

Group type: EXPERIMENTAL
Intervention: Oral azasetron
Number of subjects: 105

Group type: COMPARATOR
Intervention: Intravenous granisetron
Number of subjects: 105
Study: 20827268

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 113
Study: 18806056

Group type: EXPERIMENTAL
Intervention: Morphine (1 mg/mL)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hydromorphone (0.2 mg/mL)
Number of subjects: 50
Study: 16037760

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d
Number of subjects: 5133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5133

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 5133
Study: 12075577

Group type: EXPERIMENTAL
Intervention: PEG-OB (60 mg weekly for 8 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 28
Study: 9864107

Group type: COMPARATOR
Intervention: Monopolar electrocautery
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Ultrasonically activated shears
Number of subjects: 200
Study: 7615761

Group type: EXPERIMENTAL
Intervention: HPV-16-infected individuals
Number of subjects: 155

Group type: COMPARATOR
Intervention: General adult population (control)
Number of subjects: 155
Study: 2537721

Group type: EXPERIMENTAL
Intervention: NaHCO3 (300 mg.kg‐1 body mass)
Number of subjects: 7

Group type: COMPARATOR
Intervention: CaCO3 (placebo, 300 mg.kg‐1 body mass)
Number of subjects: 7
Study: 839852

Group type: EXPERIMENTAL
Intervention: Cephalothin
Number of subjects: 261

Group type: COMPARATOR
Intervention: Methicillin
Number of subjects: 261
Study: 6455388

Group type: EXPERIMENTAL
Intervention: Topical clindamycin phosphate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical tetracycline hydrochloride
Number of subjects: 0
Study: 31477088

Group type: EXPERIMENTAL
Intervention: Peer-led physical activity intervention (PLAN-A)
Number of subjects: 52
Study: 29324264

Group type: EXPERIMENTAL
Intervention: Four-week education program about sleep and driving
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 34
Study: 26264173

Group type: EXPERIMENTAL
Intervention: Resistance exercise during hemodialysis sessions with ankle weights and resistance bands, performed twice a week for 12 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (hemodialysis session alone)
Number of subjects: 61
Study: 24479839

Group type: EXPERIMENTAL
Intervention: Early initiation of exercise programme on post-operative day 1
Number of subjects: 77

Group type: COMPARATOR
Intervention: Late initiation of exercise programme after removal of the drain
Number of subjects: 77
Study: 22414200

Group type: EXPERIMENTAL
Intervention: SF-36 (36-item Medical Outcomes Study Short Form Survey)
Number of subjects: 9423
Study: 20854696

Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block injection
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 17986319

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgical repair followed by functional rehabilitation using tape bandage
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conservative treatment followed by functional rehabilitation with use of a functional bracing system
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgical repair
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 72
Study: 15847890

Group type: EXPERIMENTAL
Intervention: Visual inspection with acetic acid (VIA)
Number of subjects: 5010

Group type: COMPARATOR
Intervention: Cytological smears (Pap smear)
Number of subjects: 5010